March 25, 2016
On March 24th, in Louisville, KY, ASBM presented a one hour program entitled “Biosimilars: New Choices, New Challenges”, on the benefits and challenges which will accompany the arrival of biosimilars to the U.S. healthcare landscape.
March 24, 2016
On March 23, ASBM conducted an hour-long presentations entitled “Biosimilars: New Choices, New Challenges” for a group of patients and healthcare providers in St. Louis, MO.
March 24, 2016
On March 23, ASBM conducted an hour-long presentations entitled “Biosimilars: New Choices, New Challenges” for a group of patients and healthcare providers in St. Louis, MO.
February 16, 2016
On February 15th, ASBM submitted comments to Health Canada on its December 7th Guidance on Subsequent Entry Biologics (the Canadian equivalent of biosimilars), for which Health Canada has sought comment from stakeholders.
February 16, 2016
On February 15th, ASBM submitted comments to Health Canada on its December 7th Guidance on Subsequent Entry Biologics (the Canadian equivalent of biosimilars), for which Health Canada has sought comment from stakeholders.
February 10, 2016
On February 9th, the FDA’s Arthritis Advisory Committee held a hearing on CT-P13, a biosimilar to infliximab marketed internationally as Remsima or Inflectra.
February 10, 2016
On February 9th, the FDA’s Arthritis Advisory Committee held a hearing on CT-P13, a biosimilar to infliximab marketed internationally as Remsima or Inflectra.
February 5, 2016
On February 4, the House Energy and Commerce Health Subcommittee held a hearing to discuss implementation of the Biologics Price Competition and Innovation Act (BPCIA). Sean Cavanaugh, Deputy Administrator and Director of the Center for Medicare at the Centers for Medicare and Medicaid Services (CMS), and Janet Woodcock, the Director of the Center for […]
February 3, 2016
On February 2nd, ASBM’s Chairman Harry Gewanter and its Executive Director Michael Reilly participated in a panel discussion in Brussels, Belgium. The panel was held as part of a Labelling Workshop hosted by the European Biopharmaceutical Enterprises (EBE) and EuropaBio. Dr. Gewanter and Mr. Reilly discussed the findings of ASBM’s surveys of U.S. physicians and […]
January 20, 2016
On January 19th, ASBM submitted comments to the FDA supportive of reauthorizing the Biosimilars User Fee Act (BsUFA) which funds the FDA’s biosimilar program through fees paid by biosimilar sponsors: “ASBM supports reauthorization of BsUFA because the FDA must always have adequate funding and resources to bring these medicines to patients both safely and in […]
